Behind a paywall
Aging is a major cardiovascular risk factor, but the mechanisms that underlie cardiac inflammaging remain unclear. A study now shows that lymphatic rarefaction is an early determinant of cardiac aging and identifies a VEGF-C– IL-33 signaling axis that regulates lymphatic homeostasis.
https://www.nature.com/articles/s44161-026-00872-w
A person with access please post a copy.
Analyst note on sourcing: the uploaded PDF is a three-page News and Views commentary, not a primary research article. This report therefore analyzes the primary paper it discusses (Wagner et al., Nature Cardiovascular Research, 15 September 2026, open access), and uses the commentary for expert framing. All effect sizes below were calculated from the primary paper’s deposited Source Data files, not from the commentary.
Aging mouse hearts lose roughly half of their left ventricular lymphatic capillaries by 16 months and more than 85 percent by 20 to 22 months, and the authors report that this loss begins before fibrosis, thickening and relaxation failure appear. The vessels that survive are wider and have switched to sealed “zipper” junctions that take up less fluid. Cutting lymphatic density by about a third in young mice reproduced the immune cell buildup, the plasma protein leak and the relaxation defect of an old heart, which supports a causal role. The molecular trigger is the nuclear form of interleukin-33 in lymphatic endothelium, switched on by interferon gamma and held down by VEGF-C. Restoring lymphatic vessels with VEGF-C in old mice reduced inflammation but did not improve heart function.
Old hearts stiffen, collect immune cells and accumulate waste protein. A group led by Julian Wagner and Stefanie Dimmeler at Goethe University Frankfurt, working with Kari Alitalo’s lymphatic biology group in Helsinki, now reports that one of the earliest things to fail may be the heart’s own drainage system.
The heart carries a network of lymphatic vessels that clears interstitial fluid, plasma proteins and immune cells into the mediastinal lymph nodes. The team counted these vessels in mice at six ages between 3 and 22 months. Left ventricular density was already down by about half at 16 months and by more than 85 percent in the oldest animals. The right ventricle was largely spared. Surviving vessels were about a third wider, and tight “zipper” junctions, which let in less fluid than the looser “button” type, nearly tripled.
The consequences followed. Macrophages, T cells, monocytes and neutrophils accumulated in heart tissue, while macrophage numbers in the draining lymph nodes fell by half, which is what you would expect if cells could no longer leave the heart. Water content rose, the clotting protein fibrinogen built up, and amyloid deposits nearly tripled. Fibrosis and hypertrophy became obvious from 18 to 20 months. Pumping function held, while relaxation worsened slightly.
To test cause rather than coincidence, the group suppressed lymphatic growth signaling in young mice, either by deleting the receptor VEGFR3 in lymphatic cells or by releasing a decoy receptor into the circulation. Both cut vessel density by roughly a third and reproduced the macrophage buildup, the fibrinogen leak and a worsened relaxation index, with no fibrosis and no hypertrophy. Young hearts given old plumbing began to behave like old hearts.
The mechanism is the novel part. In lymphatic cells from old hearts, the IL33 gene was among the most strongly upregulated. IL-33 is best known as a secreted alarm signal, but the form that mattered here stayed in the nucleus. Forcing that form into human lymphatic cells cut division by 61 percent and raised an apoptosis marker roughly fourfold. Of the aging-associated cytokines tested, only interferon gamma, produced mainly by T and natural killer cells, switched IL33 on, acting through the JAK and STAT1 route that existing drugs already block. Pulling the other way was VEGF-C, the principal lymphatic growth factor, which declined by about a quarter in old hearts and which suppressed interferon-driven IL33 in culture.
Both brakes were released in 18-month-old mice. Silencing IL33 in endothelium raised lymphatic density by about half and cut macrophages by 41 percent. Extra VEGF-C doubled vessel density and cut macrophages by a third, yet heart relaxation did not improve after eight weeks. Function was not measured after IL33 silencing. That gap is the paper’s most informative negative result, and it points to prevention rather than late repair.
The accompanying commentary by Ebba Brakenhielm and Alma Zernecke calls the work important while flagging what is unresolved: whether lymphatic loss is the primary driver of cardiac aging or one strand of a wider process, and whether human hearts use the same nuclear IL-33 switch, which people express at higher levels than mice do.
Nothing here is a supplement or a drug you can take. Every intervention was an experimental gene therapy given to mice.
Timing looks like the main lesson. In old mice, doubling lymphatic density and cutting heart macrophages by a third did not improve heart relaxation at all (the stiffness index was 6 percent worse, a change indistinguishable from chance). Drainage repaired late did not restore performance, so protection probably has to start in mid-life. [Confidence: Medium]
Losing drainage matters. Removing about a third of the lymphatic vessels in young mice raised heart macrophages by 69 percent and worsened the stiffness index by 22 percent within two months. That is a large effect: the average treated mouse scored worse than about 95 percent of controls. With six mice per group, the true size may be smaller. [Confidence: Medium]
The practical lever with human evidence is exercise. In a trial of 61 sedentary adults averaging 53 years old, two years of structured high-intensity training raised aerobic capacity by 18 percent and reduced heart muscle stiffness (Howden et al., Circulation 2018). Separate mouse work links exercise to healthier cardiac lymphatics; the human trial did not measure them. [Confidence: Medium]
Do not self-experiment with JAK inhibitors or VEGF-C products on the strength of this paper. [Confidence: High]